Improved flexibility and economics of Calcium Looping power plants by thermochemical energy storage

Abstract In this work, a Calcium looping (CaL) system including high temperature sorbent storage is presented, allowing to reduce the size of the calciner and the associated capital-intensive equipment (ASU and CPU). Reduction of the capital costs is particularly important for power plants with low capacity factors, which is becoming increasingly frequent for fossil fuel power plants in electric energy mixes with increasing share of intermittent renewables. The process assessment is performed by: (i) defining pulverized coal power plant (PCPP) with CaL capture system with and without sorbent storage and their mass and energy balances at nominal load; (ii) defining a simple method to predict the performance of the plant at part-load; (iii) defining the economic model, including functions for the estimation of the plant equipment cost; (iv) performing yearly simulations of the systems to calculate yearly electricity production, CO2 emissions and levelized cost of electricity for different sizes of the calcination line and the storage system and (v) performing sensitivity analysis with different power production plans and carbon taxes. With this process, optimal size of the calciner and of the storage system minimizing the cost of electricity have been found. The optimal plant design was found to correspond to a solids storage system sized to manage the weekly cycling and a calciner line sized on the average weekly load. However, to avoid excessively large solids storage system, sizing the calciner on the average daily load and the storage system to manage the daily cycling appears more feasible from the logistic viewpoint and leads to minor economic penalty compared with the optimal plant design. For the selected case sized on the daily cycling, reduction of the cost of CO2 avoided between 16% and 26% have been obtained compared to the reference CaL plant without solids storage, for representative medium and low capacity factor scenarios respectively

Retrofitting partial oxyfuel and Integrated Ca-Looping technologies to an existing cement plant: a case study

The present document describes the potential retrofit of an existing cement plant with carbon capture technologies applied in two sequential steps. The pathway proposed consists in a first retrofit through partial oxyfuel followed by the integrated calcium looping (CaL) technology. This kind of applications may represent a promising strategy for the decarbonization route in the cement sector without introducing chemical solvents or special components, in particular for existing cement kilns that may need to be revamped. The cement plant selected for this study is the 0.5 Mtcem/y Colleferro facility owned by Italcementi-HeidelbergCement. This study analyses the mass & energy balances of the partial oxyfuel, and the integrated CaL process retrofitted to the existing cement plant. The results of the two CCS technologies are then compared in terms of CO2 emission reduction and energy consumption with the reference plant without CO2 capture. The scope of this analysis is to evaluate the impact of carbon capture technologies on the cement production process. The process simulation software Aspen Plus V10.0® has been employed to develop the model for the three different plant configurations (i.e., the base case w/o carbon capture, the partial oxyfuel mode, and the integrated CaL). The base case has been validated using field measurements coming directly from the Colleferro plant. From this process flow model, the two CCS technologies have been developed according to the specific process requirements. Results show that a maximum reduction in CO2 emissions of 92.4% is possible with the integrated CaL, while the partial oxyfuel enables to capture 71.7% of the CO2 generated in the plant

Techno-economic analysis of calcium looping processes for low CO2 emission cement plants

The scope of this work is to perform a techno-economic analysis of two Calcium Looping processes (CaL) for CO 2 capture in cement plants. Both tail-end CaL system with fluidized bed reactors and integrated CaL system with entrained flow reactors have been considered in the analysis. The calculation of the heat and mass balances and the economic analysis are consistent with the methodology defined in the framework of the H2020 Cemcap project. The analysis shows that the assessed CaL systems (especially the tail-end configuration) involve a significant increase of fuel consumption compared to a reference cement kiln without carbon capture. However, a large part of this additional energy input is exploited in a heat recovery steam cycle, which generates the electric power required to satisfy the consumption of the CO 2 capture auxiliaries (i.e. the power absorbed by the air separation and CO 2 compression and purification units). The integrated CaL process features a lower rise of equivalent fuel consumption (+59% compared to the reference) and a larger reduction of direct CO 2 emission (-93% compared to the reference). The specific primary energy consumption for CO 2 avoided (SPECCA), which takes into account also the indirect fuel consumption/savings and indirect emissions/avoided emissions due to electricity exchange (import/export) with the grid, ranges between 3.17–3.27 MJ LHV /kg CO2 for the integrated system vs. 3.76–4.42 MJ LHV /kg CO2 for tail-end cases, depending on the scenario considered for the grid electricity mix. The economic analysis highlights that CaL processes are capital intensive, which involve, roughly, a doubling of the Capex of the whole cement plant with CCS compared to a greenfield conventional cement plant. However, the obtained cost of CO 2 avoided is competitive with alternative technologies and ranges between about 52 €/t CO2 of the tail-end configuration and 58.6 €/t CO2 of the integrated one

Extension of the Segatella copri complex to 13 species with distinct large extrachromosomal elements and associations with host conditions

The Segatella copri (formerly Prevotella copri) complex (ScC) comprises taxa that are key members of the human gut microbiome. It was previously described to contain four distinct phylogenetic clades. Combining targeted isolation with large-scale metagenomic analysis, we defined 13 distinct Segatella copri-related species, expanding the ScC complex beyond four clades. Complete genome reconstruction of thirteen strains from seven species unveiled the presence of genetically diverse large circular extrachromosomal elements. These elements are consistently present in most ScC species, contributing to intra- and inter-species diversities. The nine species-level clades present in humans display striking differences in prevalence and intraspecies genetic makeup across human populations. Based on a meta-analysis, we found reproducible associations between members of ScC and the male sex and positive correlations with lower visceral fat and favorable markers of cardiometabolic health. Our work uncovers genomic diversity within ScC, facilitating a better characterization of the human microbiome

Comparison of technologies for CO2 capture from cement production—Part 1: Technical evaluation

A technical evaluation of CO 2 capture technologies when retrofitted to a cement plant is performed. The investigated technologies are the oxyfuel process, the chilled ammonia process, membrane-assisted CO 2 liquefaction, and the calcium looping process with tail-end and integrated configurations. For comparison, absorption with monoethanolamine (MEA) is used as reference technology. The focus of the evaluation is on emission abatement, energy performance, and retrofitability. All the investigated technologies perform better than the reference both in terms of emission abatement and energy consumption. The equivalent CO 2 avoided are 73–90%, while it is 64% for MEA, considering the average EU-28 electricity mix. The specific primary energy consumption for CO 2 avoided is 1.63–4.07 MJ/kg CO 2 , compared to 7.08 MJ/kg CO 2 for MEA. The calcium looping technologies have the highest emission abatement potential, while the oxyfuel process has the best energy performance. When it comes to retrofitability, the post-combustion technologies show significant advantages compared to the oxyfuel and to the integrated calcium looping technologies. Furthermore, the performance of the individual technologies shows strong dependencies on site-specific and plant-specific factors. Therefore, rather than identifying one single best technology, it is emphasized that CO 2 capture in the cement industry should be performed with a portfolio of capture technologies, where the preferred choice for each specific plant depends on local factors

Autoinflammation in patients with leukocytic CBL loss-of-heterozygosity is caused by constitutive ERK-mediated monocyte activation

Patients heterozygous for germline CBL loss-of-function (LOF) variants can develop myeloid malignancy, autoinflammation, or both, if some or all of their leukocytes become homozygous for these variants through somatic loss-of-heterozygosity (LOH) via uniparental isodisomy (UPD). We observed an upregulation of the inflammatory gene expression signature in whole blood from these patients, mimicking monogenic inborn errors underlying autoinflammation. Remarkably, these patients had constitutively activated monocytes that secrete 10 to 100 times more inflammatory cytokines than those of healthy individuals and CBL LOF heterozygotes without LOH. CBL-LOH hematopoietic stem and progenitor cells (HSPC) outgrew the other cells, accounting for the persistence of peripheral monocytes homozygous for the CBL LOF variant. ERK pathway activation was required for the excessive production of cytokines by both resting and stimulated CBL LOF monocytes, as shown in monocytic cell lines. Finally, we found that about 1 in 10,000

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

BACKGROUND: Acute graft-versus-host disease (GVHD) remains a major limitation of allogeneic stem-cell transplantation; not all patients have a response to standard glucocorticoid treatment. In a phase 2 trial, ruxolitinib, a selective Janus kinase (JAK1 and JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory acute GVHD. METHODS: We conducted a multicenter, randomized, open-label, phase 3 trial comparing the efficacy and safety of oral ruxolitinib (10 mg twice daily) with the investigator's choice of therapy from a list of nine commonly used options (control) in patients 12 years of age or older who had glucocorticoid-refractory acute GVHD after allogeneic stem-cell transplantation. The primary end point was overall response (complete response or partial response) at day 28. The key secondary end point was durable overall response at day 56. RESULTS: A total of 309 patients underwent randomization; 154 patients were assigned to the ruxolitinib group and 155 to the control group. Overall response at day 28 was higher in the ruxolitinib group than in the control group (62% [96 patients] vs. 39% [61]; odds ratio, 2.64; 95% confidence interval [CI], 1.65 to 4.22; P<0.001). Durable overall response at day 56 was higher in the ruxolitinib group than in the control group (40% [61 patients] vs. 22% [34]; odds ratio, 2.38; 95% CI, 1.43 to 3.94; P<0.001). The estimated cumulative incidence of loss of response at 6 months was 10% in the ruxolitinib group and 39% in the control group. The median failure-free survival was considerably longer with ruxolitinib than with control (5.0 months vs. 1.0 month; hazard ratio for relapse or progression of hematologic disease, non-relapse-related death, or addition of new systemic therapy for acute GVHD, 0.46; 95% CI, 0.35 to 0.60). The median overall survival was 11.1 months in the ruxolitinib group and 6.5 months in the control group (hazard ratio for death, 0.83; 95% CI, 0.60 to 1.15). The most common adverse events up to day 28 were thrombocytopenia (in 50 of 152 patients [33%] in the ruxolitinib group and 27 of 150 [18%] in the control group), anemia (in 46 [30%] and 42 [28%], respectively), and cytomegalovirus infection (in 39 [26%] and 31 [21%]). CONCLUSIONS: Ruxolitinib therapy led to significant improvements in efficacy outcomes, with a higher incidence of thrombocytopenia, the most frequent toxic effect, than that observed with control therapy

An explainable model of host genetic interactions linked to COVID-19 severity

We employed a multifaceted computational strategy to identify the genetic factors contributing to increased risk of severe COVID-19 infection from a Whole Exome Sequencing (WES) dataset of a cohort of 2000 Italian patients. We coupled a stratified k-fold screening, to rank variants more associated with severity, with the training of multiple supervised classifiers, to predict severity based on screened features. Feature importance analysis from tree-based models allowed us to identify 16 variants with the highest support which, together with age and gender covariates, were found to be most predictive of COVID-19 severity. When tested on a follow-up cohort, our ensemble of models predicted severity with high accuracy (ACC = 81.88%; AUCROC = 96%; MCC = 61.55%). Our model recapitulated a vast literature of emerging molecular mechanisms and genetic factors linked to COVID-19 response and extends previous landmark Genome-Wide Association Studies (GWAS). It revealed a network of interplaying genetic signatures converging on established immune system and inflammatory processes linked to viral infection response. It also identified additional processes cross-talking with immune pathways, such as GPCR signaling, which might offer additional opportunities for therapeutic intervention and patient stratification. Publicly available PheWAS datasets revealed that several variants were significantly associated with phenotypic traits such as "Respiratory or thoracic disease", supporting their link with COVID-19 severity outcome.A multifaceted computational strategy identifies 16 genetic variants contributing to increased risk of severe COVID-19 infection from a Whole Exome Sequencing dataset of a cohort of Italian patients

Peri-operative red blood cell transfusion in neonates and infants: NEonate and Children audiT of Anaesthesia pRactice IN Europe: A prospective European multicentre observational study

BACKGROUND: Little is known about current clinical practice concerning peri-operative red blood cell transfusion in neonates and small infants. Guidelines suggest transfusions based on haemoglobin thresholds ranging from 8.5 to 12 g dl-1, distinguishing between children from birth to day 7 (week 1), from day 8 to day 14 (week 2) or from day 15 (≥week 3) onwards. OBJECTIVE: To observe peri-operative red blood cell transfusion practice according to guidelines in relation to patient outcome. DESIGN: A multicentre observational study. SETTING: The NEonate-Children sTudy of Anaesthesia pRactice IN Europe (NECTARINE) trial recruited patients up to 60 weeks' postmenstrual age undergoing anaesthesia for surgical or diagnostic procedures from 165 centres in 31 European countries between March 2016 and January 2017. PATIENTS: The data included 5609 patients undergoing 6542 procedures. Inclusion criteria was a peri-operative red blood cell transfusion. MAIN OUTCOME MEASURES: The primary endpoint was the haemoglobin level triggering a transfusion for neonates in week 1, week 2 and week 3. Secondary endpoints were transfusion volumes, 'delta haemoglobin' (preprocedure - transfusion-triggering) and 30-day and 90-day morbidity and mortality. RESULTS: Peri-operative red blood cell transfusions were recorded during 447 procedures (6.9%). The median haemoglobin levels triggering a transfusion were 9.6 [IQR 8.7 to 10.9] g dl-1 for neonates in week 1, 9.6 [7.7 to 10.4] g dl-1 in week 2 and 8.0 [7.3 to 9.0] g dl-1 in week 3. The median transfusion volume was 17.1 [11.1 to 26.4] ml kg-1 with a median delta haemoglobin of 1.8 [0.0 to 3.6] g dl-1. Thirty-day morbidity was 47.8% with an overall mortality of 11.3%. CONCLUSIONS: Results indicate lower transfusion-triggering haemoglobin thresholds in clinical practice than suggested by current guidelines. The high morbidity and mortality of this NECTARINE sub-cohort calls for investigative action and evidence-based guidelines addressing peri-operative red blood cell transfusions strategies. TRIAL REGISTRATION: ClinicalTrials.gov, identifier: NCT02350348

Global maps of soil temperature

Research in global change ecology relies heavily on global climatic grids derived from estimates of air temperature in open areas at around 2 m above the ground. These climatic grids do not reflect conditions below vegetation canopies and near the ground surface, where critical ecosystem functions occur and most terrestrial species reside. Here, we provide global maps of soil temperature and bioclimatic variables at a 1-km² resolution for 0–5 and 5–15 cm soil depth. These maps were created by calculating the difference (i.e., offset) between in-situ soil temperature measurements, based on time series from over 1200 1-km² pixels (summarized from 8500 unique temperature sensors) across all the world’s major terrestrial biomes, and coarse-grained air temperature estimates from ERA5-Land (an atmospheric reanalysis by the European Centre for Medium-Range Weather Forecasts). We show that mean annual soil temperature differs markedly from the corresponding gridded air temperature, by up to 10°C (mean = 3.0 ± 2.1°C), with substantial variation across biomes and seasons. Over the year, soils in cold and/or dry biomes are substantially warmer (+3.6 ± 2.3°C) than gridded air temperature, whereas soils in warm and humid environments are on average slightly cooler (-0.7 ± 2.3°C). The observed substantial and biome-specific offsets emphasize that the projected impacts of climate and climate change on near-surface biodiversity and ecosystem functioning are inaccurately assessed when air rather than soil temperature is used, especially in cold environments. The global soil-related bioclimatic variables provided here are an important step forward for any application in ecology and related disciplines. Nevertheless, we highlight the need to fill remaining geographic gaps by collecting more in-situ measurements of microclimate conditions to further enhance the spatiotemporal resolution of global soil temperature products for ecological applications